Cipher Pharmaceuticals (CPH) Q4 2024 earnings summary

Executive summary

• Achieved significant growth in 2024, driven by the Natroba acquisition and strong Epuris performance, despite a decline in U.S. licensing revenue.

• Expanded U.S. commercial footprint and product portfolio, supporting further growth and new launches.

• Natroba acquisition in July 2024 added significant revenue and earnings, with integration and direct commercialization completed by year-end.

• Strategic focus on expanding Natroba's indications, market share in scabies, and international out-licensing opportunities.

• Initiation of a normal course issuer bid (NCIB) for share repurchases, reflecting confidence in share value.

Financial highlights

• Full year 2024 net revenue was $33.4M, up 58% from 2023; Q4 revenue was $11.8M, up 141% year-over-year.

• Product revenue grew 111% to $26.7M, with $12M from Natroba and $13M from Epuris; Q4 product revenue rose 209% to $10.5M.

• Adjusted EBITDA for 2024 was $15.7M, up 23%; Q4 adjusted EBITDA was $5M, up 73%.

• Gross margin on product revenue (excluding non-cash adjustments) was 76% for 2024 and 77% in Q4.

• Ended Q4 with $17.8M in cash, generating $8.3M in cash during the quarter; operating cash flows for 2024 were $19.5M.

Outlook and guidance

• Direct commercialization of Natroba in the U.S. expected to drive sales, margin expansion, and earnings growth in 2025.

• Focus on organic growth via Natroba's scabies indication and inorganic growth through acquisitions and in-licensing.

• Ongoing efforts to bring Natroba to Canada and out-license globally, with advanced discussions in China and the Middle East.

• Continues to execute growth strategy through portfolio leverage, new territories, and accretive acquisitions.

• No significant impact expected from tariffs or trade policies at this time.